On September 24, the Trump Administration finalized its plan to allow for the importation of prescription drugs from foreign markets. Under the plan, states could develop proposals for federal government approval to facilitate the importation of certain drugs from Canada. The Trump Administration plan is politically motivated and provides a false hope to voters that the plan would lead to lower drug costs and that the drugs would be safe.
Read MoreIn his State of the Union Address, President Trump said, “We will never let socialism destroy American healthcare.”
Yet on Sunday, September 13, the president signed and released a “Most Favored Nations” Executive Order regarding prescription drugs covered under Medicare that imports socialism into American healthcare.
Read MoreThe International Trade Commission and Department of Commerce are entertaining a request to impose a new tax of between 30 to 71% on imported Moroccan and Russian phosphate fertilizer. It’s unclear why these bureaucrats would even consider this move when producers in all countries — including the U.S. — receive government subsidies. However, what is clear is that the added fees would have significant ramifications for the entire farm community.
Read MoreCountervailing duties (CVDs) on phosphate fertilizer from Morocco and Russia would add between $100 and $250 per ton to the fob price of imported phosphate fertilizers. Based on the share of the fertilizer supply from imports, pro-rated by country market share, and the total domestic and imported supply, using the two-year average 2018-2019 fob Gulf price of MAP and DAP, the entire supply of phosphate fertilizers could see a $60 to $80 ton price increase.
This price impact could lead to an upstream $80 to $100 per ton increase in MAP and DAP fertilizer for farmers. For an N-P-K application rate of 180-70-70, that could mean a more than $7.60 per acre increase in production costs for phosphate fertilizers for U.S. farmers.
Read More
The American Edge Project is a newly formed coalition dedicated to the proposition that American innovators are an essential part of U.S. economic health, national security and individual freedoms.
The Trade Alliance to Promote Prosperity (TAPP) has long advocated for innovation in the American economy, especially by protecting intellectual property rights. TAPP has joined the American Edge Project in a coalition to maintain “America’s edge” through smart regulatory and policy strategies to preserve an open and accessible digital environment.
Read MoreToday, the U.S. International Trade Commission voted to continue investigations concerning phosphate fertilizers being imported from Morocco and Russia. The Trade Alliance to Promote Prosperity denounces this vote and the corresponding investigation.
Read MoreIn his State of the Union Address, President Trump said, “We will never let socialism destroy American healthcare.”…
Read MoreSeveral states’ attorneys general have made an egregious request to the federal government to subvert the patent rights of Gilead Sciences, Inc., the manufacturer of Remdesivir, which has been fast-tracked by the U.S. Food and Drug Administration (FDA) and has shown promising results in reducing the risk of death and length of hospitalization for COVID-19 patients…
Read MoreToday, eight prominent Republican U.S. Senators wrote to Commerce Secretary Wilbur Ross and International Trade Commission Chairman Jason Kearns and urged them to deny Mosaic’s petition.
Read MoreFarmers face an uphill battle every year, it seems—from bad weather, to weed infestations, to insect invasions. On top of this, farmers have recently had to contend with trade wars and, now, COVID-19. This year was supposed to be a moderately good year for farmers, but then COVID-19 hit, and now the agriculture industry is expecting to experience a downturn of over 20%, according to the Food and Agriculture Policy Research Institute at the University of Missouri…
Read MoreOn Friday, President Trump issued an executive order to implement what is known as the international pricing index (IPI) model for Medicare Part B drugs and biologicals. The ostensible goal of the executive order is to lower drug prices. This supposedly would be accomplished by pegging the price that the Medicare system pays for drugs to a level closer to the prices paid in a collection of other countries…
Read MorePresident Trump issued an executive order this Friday afternoon that will implement an international pricing index (IPI) model for Medicare Part B drugs and biologicals. This executive order purports to lower drug prices by linking the price paid through Medicare for drugs to prices in a number of foreign countries…
Read MoreOn Wednesday July 8, 2020, Joe Biden and Bernie Sanders “unity task force” unveiled a new health care plan that would expand Obamacare and move towards Sanders’ proposed “Medicare for all”. (1) The plan would be a detriment to the American health care systems by weakening intellectual property rights, imposing a restrictive inflationary penalty, and expanded restriction on federal funding…
Read MoreArtificially limiting America’s supply chain of raw materials for medicines and vaccines would have irrevocable effects on public health and the economy.
Read MoreAs a result of COVID-19 and mandated business shutdowns in most states, over 37 million Americans have been thrown out of work, thereby losing their health insurance benefits…
Read MoreWe cannot predict where the palliative therapies or the cure for COVID-19 will originate, but we know that the United States biopharmaceutical industry is well-positioned to help in their discovery because our country has aligned incentives to achieve the objective of providing the most innovative environment—including strong IP protections.
Read MoreThe Trump Administration is reportedly poised to issue an executive order that would affect the production of medicines, FDA-regulated emergency medical countermeasures, and active pharmaceutical ingredients. This is a terrible idea, especially during a pandemic…
Read MoreU.S. Senator Chuck Grassley (R-Iowa) is making a big push for new cosponsors of the Prescription Drug Pricing Reduction Act (PDPRA, a.k.a. the Grassley-Wyden Prescription Drug Bill), building off of President Trump’s mention of reducing prescription drug prices during his 2020 State of the Union address. Although Sen. Grassley has had trouble getting Republican Cosponsors in past, the State of the Union address has emboldened his staff to recirculate a recruitment letter, netting Sens. McSally (R-Arizona) and bringing the bill up to almost a dozen Republican cosponsors…
Read MoreThe Trump administration has been toying with the idea of implementing an international pricing index (IPI) model for Medicare Part B drugs and biologicals. The ostensible goal of the model would be to lower drug prices. This supposedly would be accomplished by pegging the price that the Medicare system pays for drugs to a level closer to the prices paid in a collection of other countries…
Read More
The Trump Administration has been toying with the idea of implementing an international pricing index (IPI) model for Medicare Part B drugs and biologicals. The ostensible goal of the model would be to lower drug prices. This supposedly would be accomplished by pegging the price that the Medicare system pays for drugs to a level closer to the prices paid in a collection of other countries…
Read More